General Information of Drug (ID: DMPRIHK)

Drug Name
Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells Drug Info
Synonyms
Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMPRIHK

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 6.226 7.169 7.196 6.397
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 5.67E-03 -1.26 -2.05
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034.
2 Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.